Most tirzepatide myths start with one true detail and stretch it too far. Tirzepatide isn't a steroid, and it isn't "natural." Weight loss on it slows and levels off, but that isn't the drug quitting. Stopping usually brings weight back, though not all of it overnight. Nobody knows yet whether it causes thyroid cancer in people. And compounded tirzepatide is not Zepbound. Here are nine things people say about it, each checked against the trials and the current label.
Tirzepatide myths and facts: how the grades work
Each claim gets one of four grades. Supported means it holds up as stated. Partly means one piece is right but the conclusion goes too far. Not supported means the evidence doesn't back it. Unknown means nobody has good enough data yet.
1. "Tirzepatide is just a stronger semaglutide."
Partly. In a 72-week head-to-head trial of 751 adults with obesity but not diabetes, people on tirzepatide lost 20.2% of their body weight on average, against 13.7% on semaglutide (SURMOUNT-5, Aronne and colleagues, NEJM 2025). The trial was open-label, meaning everyone knew which drug they were on. On average weight loss in that trial, "stronger" held up.
"Just" is where the claim breaks. Tirzepatide is its own molecule, designed to switch on two hormone receptors, GIP and GLP-1, where semaglutide switches on one (Coskun and colleagues, Molecular Metabolism 2018); how tirzepatide works explains each signal. It also has its own record. As of September 22, 2026, the day this article was written, the Mounjaro label, revised in August 2026, covers lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk, based on a 13,299-person trial where tirzepatide proved no worse than another GLP-1 drug, dulaglutide, though it wasn't shown to be better.
2. "Tirzepatide is a steroid."
Not supported. Steroids are fat-based molecules with a four-ring shape, like cortisol and testosterone. Tirzepatide is a peptide: a chain of 39 amino acids (the building blocks of proteins) with a fatty-acid tail that lets one dose last a week. It acts on gut-hormone receptors, not steroid receptors. Is tirzepatide a peptide? covers the classification.
3. "It's a peptide, so it's natural."
Not supported. Your body makes GIP and GLP-1. It doesn't make tirzepatide. It's built on GIP's sequence, then altered: two of its amino acids aren't ones the body uses to build proteins, and a 20-carbon fatty-acid chain is attached so it clings to albumin, a blood protein, and clears slowly (current Zepbound label, revised August 2026). It's an engineered medicine, and "natural" was never a synonym for safe.
4. "Tirzepatide melts your muscle."
Partly. Some of the weight lost is lean tissue, but not out of proportion. In a 160-person SURMOUNT-1 substudy using DXA scans (a low-dose X-ray that separates fat from lean tissue), people on tirzepatide lost 21.3% of their weight over 72 weeks; about 74% of that loss was fat and 26% lean mass. The placebo group, with the same diet and activity counseling, lost less weight in nearly the same split, 75% and 25% (Look and colleagues, Diabetes, Obesity and Metabolism 2025).
Lean mass isn't the same as muscle; it also counts water, organs and connective tissue. A review of 60 studies across this drug family, published September 12, 2026, found lean mass falls largely in step with weight loss, mostly in liraglutide and semaglutide studies, but rated that evidence low-certainty and called the effect on strength unclear (Beaudart and colleagues, Drugs 2026). Tirzepatide and exercise covers the strength question. Drugs built specifically to protect muscle during GLP-1 weight loss are still in trials; the first therapy approved to target muscle loss, apitegromab, is approved only for spinal muscular atrophy.
5. "All the weight comes back the moment you stop."
Partly. Regain is common, but "all" and "the moment" don't match the data. In SURMOUNT-4, 670 adults who had lost an average of 20.9% over 36 weeks were split: half stayed on tirzepatide, half switched to placebo. Over the next year the placebo group's weight rose 14.0%, yet they still averaged 9.9% below where they started. Only 16.6% of them kept at least 80% of their loss, against 89.5% of those who stayed on the drug (Aronne and colleagues, JAMA 2024). What happens when you stop taking tirzepatide has the month-by-month picture.
6. "Tirzepatide stops working after a few months."
Not supported. What people notice is a plateau, when weight loss slows and levels off, and that's expected. In a post-hoc analysis (a second look at finished trial data) of SURMOUNT-1, about 88% to 90% of people who stayed on treatment and lost at least 5% had reached a plateau by week 72, typically between about 24 and 36 weeks in, depending on starting weight (Horn and colleagues, Clinical Obesity 2025).
A plateau is a new balance, not a drug that has quit. In SURMOUNT-4, people who kept taking tirzepatide after 36 weeks lost a further 5.5% over the next year. The tirzepatide plateau explains what a prescriber reviews when the scale stalls.
7. "Tirzepatide causes thyroid cancer in people."
Unknown. The label's boxed warning, the strongest a U.S. drug label carries, rests on rat studies: tirzepatide caused thyroid C-cell tumors in rats, and the human relevance "has not been determined." The branded drug is ruled out for anyone with a personal or family history of medullary thyroid carcinoma, a rare cancer of those C cells, or MEN 2, an inherited syndrome that raises that risk. Tirzepatide and thyroid cancer walks through the human studies.
8. "Compounded tirzepatide is the same as Zepbound."
Not supported. Zepbound is a finished brand product with its own formulation, pen and manufacturing record. A compounded prescription is prepared by a pharmacy for one patient and can differ in concentration, inactive ingredients and container. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA says compounded drugs don't go through its review for safety, effectiveness or quality before they're sold.
It isn't a generic, either: a generic is a copy that must pass its own FDA review for sameness. As of September 22, 2026, the day this article was written, no generic tirzepatide had been approved; Sandoz announced on June 29, 2026 that FDA had accepted two of its generic applications for review (Sandoz). Compounded tirzepatide covers the rules.
9. "You can't drink any alcohol on tirzepatide."
Not supported as an absolute. Neither the current Mounjaro nor the Zepbound label lists alcohol as an interaction or a warning; the word appears only as an inactive ingredient and on the injection swab. That isn't a green light. The labels warn about severe stomach and gut side effects, kidney injury from dehydration, pancreatitis, and low blood sugar when tirzepatide is combined with insulin or a sulfonylurea (an older type of diabetes pill), and drinking can pile onto each. Tirzepatide and alcohol goes through each risk.
Where semaglutide fits
Several of these myths travel between the two drugs, and so do the answers: semaglutide is also an engineered peptide, carries the same kind of thyroid boxed warning, and also sees weight return after stopping. It's still a different medicine, so switching is a new treatment decision, not a workaround. Semaglutide myths checks the same claims for that drug.
Why the prescription route matters
Most myths point at a real question: family thyroid history, how much you drink, whether you take insulin, what happens if you stop. Those are exactly what a prescriber weighs, and they're easier to answer honestly with a person than with a comment thread.
At Promise, a licensed provider reviews every request, and not everyone qualifies. A licensed provider may still prescribe compounded tirzepatide when it fits a patient's needs; that decision is between the patient and the doctor. The review is also where the honest answers live, including "partly" and "we don't know yet."
